Clinical trials: Depression NOS
Major Depression
Cimicoxib for the Treatment of Major Depression (SECIM)
This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression.
- Trial name
- NCT00510822
- Testing
- Cimicoxib
- Where
- 25 sites in Austria, Czechia and 1 more
- Volunteers
- 169 people
- Sponsor
- Affectis Pharmaceuticals AG
Depression
AZD6765 for Treatment Resistant Depression
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
- Trial name
- NCT00491686
- Testing
- AZD6765
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Alcohol Abuse, Alcohol Abuse/addiction
A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder
This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.
- Conditions
- Alcohol Abuse, Alcohol Abuse/addiction, Anxiety, Pain Threshold
- Trial name
- NCT06710431
- Testing
- AFA-281
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Afasci Inc
Major Depressive Disorder
A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe Depression
The purpose of this study is to evaluate the safety and effectiveness of JNJ-18038683 compared to escitalopram and placebo in patients with moderate to severe depression.
- Trial name
- NCT00566202
- Testing
- Escitalopram, JNJ-18038683
- Where
- 26 sites in United States
- Volunteers
- 67 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression, Anxiety
Integrating a Suite of Mental Health Apps for Depression in a Healthcare Setting
The purpose of this study is to evaluate the implementation of IntelliCare as a frontline intervention within health care settings.
- Trial name
- NCT05274620
- Testing
- IntelliCare
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Adaptive Health, Inc
Depressive Disorders, Psychotic Disorders
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized…
- Conditions
- Depressive Disorders, Psychotic Disorders, Depression
- Trial name
- NCT00844922
- Testing
- SCH 900636
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression
To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Bupropion HCI 300 mg ER Tablets under fasting conditions.
- Trial name
- NCT00861939
- Testing
- Bupropion HCI 300 mg Extended-Release Tablets EON, WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and sexual function in women who are perimenopausal or…
- Conditions
- Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction
- Trial name
- NCT07413705
- Testing
- EXOMIND (BTL-699-2) Active Treatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- BTL Industries Ltd.
Major Depressive Disorder
EEG Biomarkers for Predicting Response to Antidepressant Therapy
The purpose of this study is to evaluate the potential early EEG predictors of an individual's response to treatment with antidepressant medications.
- Trial name
- NCT00289523
- Where
- 10 sites in United States
- Volunteers
- 375 people
- Sponsor
- Medtronic - MITG
Bipolar Disorder
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks.
- Trial name
- NCT00083954
- Testing
- Quetiapine Fumarate
- Where
- 36 sites in United States
- Volunteers
- 530 people
- Sponsor
- AstraZeneca
Depression
Artificial Intelligence in Depression - Medication Enhancement
This study will determine the safety and potential effectiveness of a digital health platform aimed at improving treatment outcomes for patients with depression by assisting physicians with clinical decision making about…
- Trial name
- AID-ME (NCT04655924)
- Testing
- Clinical Decision Support System
- Where
- 11 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Aifred Health
Depression, COVID-19
Effectiveness and Tolerability of аgomelatine in the Treatment of Patients With Depression After SARS-CoV-2 (TELESPHOR)
This is a multi-centre, observational, non-interventional study, which will prospectively collect clinical and socio-demographic data from patients with depression occurred after COVID 19 in real clinical settings during 8 weeks…
- Trial name
- TELESPHOR (NCT05323994)
- Where
- Russia
- Volunteers
- 104 people
- Sponsor
- Servier Russia
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients
Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS / MS) is a medical entity characterized mainly by debilitating and prolonged fatigue lasting more than 6 months, post-exertion fatigue (physical and / or…
- Trial name
- NCT04301609
- Testing
- Active
- Where
- Spain
- Volunteers
- 67 people
- Sponsor
- Vitae Health Innovation
Major Depressive Disorder
International Study to Predict Optimised Treatment - in Depression
The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants treatment (Escitalopram, Venlafaxine…
- Trial name
- iSPOT-D (NCT00693849)
- Testing
- Escitalopram, Sertraline, Venlafaxine-XR
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 2,688 people, healthy volunteers welcome
- Sponsor
- BRC Operations Pty. Ltd.
Major Depressive Disorder
Fisher Wallace Neurostimulation & Depression Study
Examine the safety and effectiveness of the Fisher Wallace Cranial Electrotherapy Stimulator Device on Major Depressive Disorder using two 20-minute per day treatment sessions over eight weeks.
- Trial name
- NCT04541563
- Testing
- Fisher Wallace Cranial Electrotherapy Stimulator Device
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- ProofPilot
Insomnia, Depression
Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression
The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.
- Trial name
- NCT00232167
- Testing
- Indiplon, Sertraline
- Volunteers
- 380 people
- Sponsor
- Neurocrine Biosciences
Depression
Study Evaluating Effexor XR for Major Depression.
Study Evaluating Effexor XR for Major Depression.
- Trial name
- NCT00225511
- Testing
- Effexor XR, Milnacipran
- Where
- 73 sites in Japan
- Volunteers
- 590 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
This is a multiple-dose study to assess the safety and pharmacology of ABT-436 in physically healthy subjects with mild to moderate depressive symptoms who are not taking any antidepressant medication.
- Trial name
- NCT01380704
- Testing
- ABT-436
- Volunteers
- 51 people
- Sponsor
- AbbVie
Major Depressive Disorder
Self-guided Treatment for Depression
This study will examine the efficacy and safety of a self-guided digital therapeutic app for the adjunct treatment of Major Depressive Disorder compared to a control app in adolescents and adults.
- Trial name
- NCT06028984
- Testing
- Intervention app, Control app
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Big Health Inc.
Major Depressive Disorder
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
The purpose of this study is to determine the effectiveness and safety of vortioxetine, once daily (QD), in patients with Major Depressive Disorder.
- Trial name
- NCT00735709
- Testing
- Vortioxetine
- Where
- 48 sites in Australia, Czechia and 13 more
- Volunteers
- 560 people
- Sponsor
- Takeda